UNITES
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): April 7, 2016
NEPHROS,
INC.
(Exact
name of Registrant as Specified in its Charter)
Delaware
(State or other jurisdiction
of incorporation) |
|
001-32288
(Commission
File Number) |
|
13-3971809
(IRS Employer
Identification No.) |
41
Grand Avenue, River Edge, New Jersey 07661
(Address of principal executive offices, including ZIP code)
(201)
343-5202
(Registrant’s telephone number, including area code)
Not
Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
| [ ] |
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
|
| [ ] |
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
|
| [ ] |
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
|
| [ ] |
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item
8.01 Other Events.
As
previously disclosed, on May 27, 2015, Nephros, Inc. (the “Company”) received a warning letter (the “Warning
Letter”) from the U.S. Food and Drug Administration (the “FDA”) resulting from inspections of the Company’s
facility in River Edge, New Jersey by the FDA’s New Jersey District Office that occurred in October 2014. Subsequent to
that date, the Company responded to the Warning Letter and worked to resolve the issues raised by the FDA. On August 12, 2015,
the Company received a subsequent letter (the “Subsequent Letter”) from the FDA noting that it had received the Company’s
response correspondence to the Warning Letter detailing the Company’s completed corrective actions. The corrective actions
included revisions to the Company’s standard operating procedures relating to purchasing and supplier controls, adverse
event reporting, and complaint handling and monitoring. The Subsequent Letter also noted that the FDA would verify the Company’s
implementation of corrective measures at its next inspection of the Company’s facility. Neither the Warning Letter nor the
Subsequent Letter restricted the manufacture, production or shipment of any of the Company’s products, nor did they require
the withdrawal of any product from the marketplace. In February 2016, the FDA performed another on-site inspection. There were
no observations, or 483’s, cited at the conclusion of the inspection.
On
April 7, 2016, the Company received a letter (the “Third Letter”) from the FDA noting that the FDA has completed its
evaluation of the Company’s corrective actions in response to the Warning Letter and that, based on this evaluation, it
appears that the Company has addressed the violations contained in the Warning Letter. A copy of the Third Letter is attached
hereto as Exhibit 99.1.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
Exhibit
No. |
|
Description |
| |
|
|
| 99.1 |
|
Letter
from the U.S. Food and Drug Administration to Nephros, Inc. dated April 7, 2016. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf
by the undersigned hereunto duly authorized.
| |
Nephros,
Inc. |
| |
|
|
| Dated:
April 11, 2016 |
By: |
/s/
Daron Evans |
| |
|
Daron
Evans |
| |
|
President
& Chief Executive Officer |
Index
to Exhibits Filed with this Report
Exhibit
No. |
|
Description |
| |
|
|
| 99.1 |
|
Letter
from the U.S. Food and Drug Administration to Nephros, Inc. dated April 7, 2016. |
